| Q24679426 | APC-derived cytokines and T cell polarization in autoimmune inflammation |
| Q34328201 | Activated human CD4+CD45RO+ memory T-cells indirectly inhibit NLRP3 inflammasome activation through downregulation of P2X7R signalling |
| Q43173955 | Anti-inflammatory effect of pigment epithelium-derived factor in DBA/2J mice |
| Q46279808 | Cell Death Pathways: a Novel Therapeutic Approach for Neuroscientists. |
| Q38687394 | Close Encounters of the First Kind: Innate Sensors and Multiple Sclerosis. |
| Q34501875 | Complementing the inflammasome. |
| Q52143402 | Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability. |
| Q34212591 | Deregulated inflammasome signaling in disease |
| Q61795797 | Dexmedetomidine inhibits astrocyte pyroptosis and subsequently protects the brain in in vitro and in vivo models of sepsis |
| Q48141250 | Differential contribution of microglia and monocytes in neurodegenerative diseases. |
| Q92992581 | Gasdermin D in peripheral myeloid cells drives neuroinflammation in experimental autoimmune encephalomyelitis |
| Q37873072 | How do immune cells overcome the blood-brain barrier in multiple sclerosis? |
| Q41990044 | How inflammasomes inform adaptive immunity |
| Q38124723 | IL-18 in inflammatory and autoimmune disease |
| Q52332793 | Inflammasome Proteins As Biomarkers of Multiple Sclerosis. |
| Q39044498 | Inflammasome activation in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). |
| Q34701729 | Inflammasome activation in obesity-related inflammatory diseases and autoimmunity. |
| Q34670542 | Inflammasomes and autoimmunity |
| Q47593693 | Inflammasomes in neurological diseases: emerging pathogenic and therapeutic concepts |
| Q94948176 | Inhibition of the NLRP3-inflammasome prevents cognitive deficits in experimental autoimmune encephalomyelitis mice via the alteration of astrocyte phenotype |
| Q38156767 | Initial immunopathogenesis of multiple sclerosis: innate immune response. |
| Q37348839 | Interferon-beta treatment in multiple sclerosis attenuates inflammatory gene expression through inducible activity of the phosphatase SHP-1. |
| Q36431053 | Interferon-β therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome |
| Q54372515 | Interleukin 18 activates MAPKs and STAT3 but not NF-κB in hippocampal HT-22 cells. |
| Q34095673 | Interleukin 18 in the CNS. |
| Q54434473 | Interleukin 18 receptor 1 expression distinguishes patients with multiple sclerosis. |
| Q36704477 | Interleukin-18 genetics and inflammatory disease susceptibility |
| Q46572704 | Involvement of inflammation, degradation, and apoptosis in a mouse model of glaucoma |
| Q38177270 | Licensing Adaptive Immunity by NOD-Like Receptors |
| Q37301528 | Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype |
| Q55378559 | Monosodium Urate Crystals Activate the Inflammasome in Primary Progressive Multiple Sclerosis. |
| Q92999906 | Multiple Sclerosis patients carry an increased burden of exceedingly rare genetic variants in the inflammasome regulatory genes |
| Q52147613 | Myelin-specific T cells induce interleukin-1beta expression in lesion-reactive microglial-like cells in zones of axonal degeneration. |
| Q49516622 | NLR-Dependent Regulation of Inflammation in Multiple Sclerosis- Dependent Regulation of Inflammation in Multiple Sclerosis |
| Q36566053 | NLRP3 Inflammasome and MS/EAE. |
| Q29248417 | NLRP3 Inflammasome in Neurological Diseases, from Functions to Therapies |
| Q30519470 | NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis |
| Q36670359 | NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses |
| Q37954043 | Nucleotide-binding oligomerization domain-like receptors and inflammasomes in the pathogenesis of non-microbial inflammation and diseases |
| Q36091339 | Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-β 1a treated multiple sclerosis patients |
| Q51756481 | Retinal ganglion cell protection by 17-beta-estradiol in a mouse model of inherited glaucoma. |
| Q37729175 | The Characterization of GSDMB Splicing and Backsplicing Profiles Identifies Novel Isoforms and a Circular RNA That Are Dysregulated in Multiple Sclerosis. |
| Q53287408 | The Inflammasome Sensor, NLRP3, Regulates CNS Inflammation and Demyelination via Caspase-1 and Interleukin-18 |
| Q59339809 | The physiology of foamy phagocytes in multiple sclerosis |
| Q38077590 | The role of interferon-β in the treatment of multiple sclerosis and experimental autoimmune encephalomyelitis - in the perspective of inflammasomes |
| Q40085017 | Transcriptional dysregulation of Interferome in experimental and human Multiple Sclerosis |
| Q40061942 | Transcriptomic Analyses Reveal Differential Gene Expression of Immune and Cell Death Pathways in the Brains of Mice Infected with West Nile Virus and Chikungunya Virus |